NCT07251673

Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Assistance Publique - Hôpitaux de Paris · Academic / Other
• Sex: All
• Age: 6 Months – 21 Years
• Healthy volunteers: Not accepted

Summary

Dravet syndrome with SCN1A gene mutation is a developmental and epileptic encephalopathy characterized by treatment-resistant epilepsy and global developmental delay. Despite the considerable attention recently Dravet syndrome (DS) in drug development, studies characterising the progression of the neurodevelopmental phenotype over time remain limited. In particular, many previous studies of natural history studies have been of short duration or have focused only on a subgroup of the paediatric population. This prospective natural history study is being conducted to define more precisely the neurodevelopmental trajectory of SCN1A-positive Dravet syndrome in patients aged aged 6 months to 21 years with SCN1A mutations. The study will examine these characteristics over a 4-year period using standardised assessments. The study will also explore potential metabolomic biomarkers and their relationship with clinical outcomes.

Detailed description

A prospective cohort to document the evolutionary trajectory over a 4-year period of patients with Dravet syndrome with a confirmed pathogenic or probably pathogenic variant in the SCN1A gene aged between 6 months and 21 years. Pre-selection/eligibility stage Patients and their legal representatives will be contacted by an investigator. Inclusion and non-inclusion criteria will be assessed to confirm the participant's eligibility, allowing entry into the study and completion of the baseline assessment. Following a discussion of the objectives, risks and benefits of the study, the patient's non-objection to taking part in the research will be obtained, together with the patient's assent, if applicable. Baseline assessment (Year 0) An initial visit will be organized to collect demographic, historical and clinical data, and to carry out : 1. A detailed medical assessment (age, sex, history of seizures genetic diagnosis, co-morbidities, current treatments). 2. The Vineland-3 (parental module), analyzed by a psychologist 3. GMFM-66 for motor functions (by a physiotherapist). 4. CGI-S scale (clinician and carer) 5. An additional tube of blood taken during a blood test for metabolomics analysis (including serum GABA). 6. Bayley-IV (up to 8 years, depending on chronological or developmental age). Annual visits (Years 1 to 4) Annual assessments will be carried out to document clinical progress and will include: 1. A medical update (new diagnoses, types and frequency of seizures, treatments). 2. The same assessment tools as at the initial visit (Vineland-3, GMFM-66, CGI-S, Bayley-IV). 3. The CGI-I scale to measure changes since the previous visit. 4. An extra tube of blood taken during a blood test for metabolomics for metabolomic analysis. 5. The collection of data from medical examinations carried out as part of the treatment. End of the study After four annual visits following the baseline assessment, the participant will complete the study. A final report will be drawn up to document the clinical and functional evolution of Dravet syndrome over a 4-year period

Conditions

• Dravet Syndrome

Timeline

• Start date: 2025-09-15
• Primary completion: 2030-10-01
• Completion: 2030-10-01
• First posted: 2025-11-26
• Last updated: 2026-02-03

Locations

1 site across 1 country: France